ADARA announces expansion into the Nordics and plans for further European growth
ADARA, the leader in predictive traveller intelligence, today announces its expansion into the Nordic market for the first time, with the appointment of Jonas Jonsborg as Regional Manager, Nordics ADARA. In addition to the hire, ADARA also announces new recent data partnerships with Momondo, HotelsCombined and Cheapflights, which will further bolster its presence in Europe and support brands in the region.
Comprising over 850 million monthly unique traveller profiles across more than 200 leading travel brands, ADARA’s travel data co-op offers a holistic view of traveller behaviour and preferences along the entire customer journey. Since expanding into the region in 2013, ADARA has established a strong presence in Europe with the appointment of Curtis Nishijima as Managing Director, EMEA in 2018 and with key hires in the UK, Germany, France and Spain. ADARA has also seen an increase in its EMEA data profiles of 38% year on year, furthering bolstering their data presence in the region.
Building on the success in these markets, ADARA is now strengthening its presence in the Nordics, one of the fastest-growing travel markets in EMEA. Tourism in the Nordics has seen a significant rise in recent years; since 2014 the region had an annual growth of 6% - 8.5% in the number of hotel nights. The expansion seeks to enable travel brands and agencies to tap into the increased demand by tourists to and from the Nordic region by offering holistic data insights that can be used to create personalised marketing campaigns based on the complete view of the traveller.
The depth and applicability of ADARA’s data go beyond the travel and tourism industries. Other sectors in the Nordics such as luxury retail, financial services and automotive can also take advantage of ADARA’s understanding of traveller purchase behaviour and ADARA can provide these brands with solutions that improve marketing performance and help achieve deeper personalisation using actionable data.
In his new role, Jonas will spearhead ADARA’s expansion into the Nordic markets, drawing on his extensive understanding and experience in data and advertising technology. Jonas has previously held executive positions at Adform, Microsoft, Meetrics and Audience Project.
Jonas Jonsborg, Regional Manager at ADARA Nordics said: “The Nordic market is experiencing a huge gap, one that can only be filled by ADARA. The breadth and depth of the data is unparalleled, and will be invaluable to Nordic partners. I look forward to leveraging my experience in the Nordics and strong belief in ADARA’s value proposition to grow the business and establish new data partners in the region.”
Curtis Nishijima, Managing Director, EMEA said “Jonas has an exceptional range of skills that make him the perfect person to spearhead our Nordic expansion. He has a strong knowledge of the region and a deep understanding of our industry.
-ENDS-
About Momondo
Momondo is a travel fare aggregator and travel fare metasearch engine headquartered in Copenhagen. Momondo also operates a travel information blog, Inspiration. The website is part of the Kayak.com subsidiary of Booking Holdings.
About Hotelscombined
HotelsCombined, a unit of Booking Holdings, is a hotel metasearch engine founded in 2005. The site operates in over 42 languages, handles 130 different currencies and aggregates more than 2 million deals from hundreds of travel sites and hotel chains.
About Cheapflights
Cheapflights is a travel fare aggregator and travel fare metasearch engine headquartered in London, UK. The website is part of the Kayak.com subsidiary of Booking Holdings. Its websites publish flight prices, and compare prices from suppliers, including major airlines, through tiny travel agents.
About ADARA
ADARA. Know What Travellers Need Next.
ADARA empowers the world's leading travel brands to grow the industry together. Built on the world's richest travel data co-op, ADARA offers people-based insights for travel companies. Clients get a value-based understanding of their relationship with their customers, with travel patterns, trends and behavior from more than 850 million monthly unique traveler profiles across more than 200 of the world's top travel brands. ADARA delivers critical intelligence to activate personalisation and relevance throughout the customer journey for sustainable growth. Its offerings span the three core pillars – Learn, Act, Measure & Modify – to drive measurable outcomes at the customer level. https://www.adara.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191106005106/en/
Contact information
For more information please contact:
Ben Tozer / Louise Watson
adara@propellergroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant Group Unveils China’s First Multimodal AI Assistant with Code-Driven Outputs18.11.2025 10:05:00 EET | Press release
Ant Group today launched LingGuang, a next-generation multimodal AI assistant and the first of its kind in China that interacts with users through code-driven outputs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117438567/en/ Equipped with the capability to understand and produce language, image, voice and data, LingGuang delivers precise, structured responses to complex queries through 3D models, audio clips, charts, animations, interactive maps, and even immediately generated applications, in addition to traditional text-based conversation. Designed around three key features, LingGuang aims to make complex knowledge simpler and more intuitive, transforming how users access information and interact with AI tools. Fast Research: LingGuang responds to user questions or keywords with dynamic, multimodal content, making research on any topic clearer and more engaging. Its 3D digital modeling capability transcends traditio
SkySparc Appoints Oliver Bussmann as Chairman of the Board18.11.2025 10:00:00 EET | Press release
SkySparc, a trusted global provider of digital transformation solutions for treasury and finance organizations, today announced the appointment of Oliver Bussmann as Chairman of the Board, following the closing of a majority growth investment from Bregal Milestone, a leading European software private equity firm. As former Global CIO at UBS and SAP, Bussmann has a proven track record of scaling B2B software and services across the Office of the CFO, Financial Services, RegTech, and WealthTech. Throughout his career, he has guided organizations through complex SaaS transitions, strategic M&A, and go-to-market acceleration – delivering multiple successful exits and sustained enterprise growth. Bussmann will help steer SkySparc’s technology and value-creation agenda, as Chairman, leveraging his network across financial services and technology to accelerate innovation, expand AI adoption, and drive long-term growth. “We are thrilled to welcome Oliver to SkySparc’s leadership team,” said Jo
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 09:23:00 EET | Press release
Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline infusion preparation, reduce healthcare professionals’ workload, and support hospital operational efficiency.3 The Remsima™ IV liquid formulation is approved in the EU for all indications of IV infliximab, matching the approved uses of all existing IV infliximab powder formulations, including rheumatoid arthritis (RA), adult and pediatric Crohn’s disease (CD), ulcerative colitis (UC), pediatric UC, ankylosing spondylitis (AS), psoriatic arthritis (PsA), and psoriasis (PsO).1 The comparability between lyophilized powder formulation and the liquid formulation of IV infliximab has been established through comprehensive chemistry, manufacturing, and controls data.2 The stability of the liquid formulation of I
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 09:00:00 EET | Press release
Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approaches for combating cancer. IDEAL Japan follows the conclusion of the highly respected JCA (Japanese Cancer Association) Mauvernay Award in Japan, which honored Japanese scientists over the last 20 years, from 2004 through 2024. Debiopharm is now transitioning its historic award into the IDEAL Japan initiative aiming to accelerate preclinical scientific research that could give rise to new treatments for cancer patients. “Our vision is to collaborate to find a cure for cancer,”explained Thierry Mauvernay, President of Debiopharm. “We believe that our ongoing Swiss-Japanese connection needs to evolve and catalyze the trans
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 08:00:00 EET | Press release
Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117345890/en/ Adam Plich, Founder and CEO of Avanzanite. The announcement follows a record-breaking Q3 2025 for Avanzanite, with revenue tripling year-on-year and climbing over 20% quarter-on-quarter. This strategic funding will accelerate the expansion of Avanzanite’s pan-European infrastructure and propel both current and future rare disease product launches. The capital will also enable Avanzanite to form new strategic alliances and acquire assets to expand its portfolio. Avanzanite was built to solve Europe’s rare-disease medicines access gap. Under one pan-European operation, Avanzanite brings toget
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom